Is eNAMPT/visfatin a potential serum marker of papillary thyroid cancer?
Purpose: The role of nicotinamide phosphoribosyltransferase (NAMPT)/visfatin in a more aggressive course of many malignancies has been proven. Previous studies have noticed the importance of visfatin in thyroid neoplastic tissue, but the diagnostic and prognostic value of its serum concentration has not been investigated so far. Our study aimed to consider whether extracellular NAMPT (eNAMPT) could be a potential serum marker in recurrent papillary thyroid cancer (PTC).
Methods: It was a prospective observational study with consecutive enrolment. We recruited 100 patients with PTC after thyroidectomy with postoperative
Results: The visfatin serum concentrations in patients diagnosed with PTC and in healthy subjects were not statistically significantly different (
Conclusion: We have not found visfatin as a potential serum marker of papillary thyroid cancer. Also, eNAMPT has no prognostic value in assessing the risk of disease recurrence or metastasis in PTC management.
Published In/Presented At
Sawicka-Gutaj N, Ziółkowska P, Derwich A, Gut P, Czarnywojtek A, Kloska M, Ruchała M. Is eNAMPT/visfatin a potential serum marker of papillary thyroid cancer? Ther Adv Endocrinol Metab. 2022 Apr 13;13:20420188221090005. doi: 10.1177/20420188221090005. PMID: 35450096; PMCID: PMC9016592.
Medicine and Health Sciences
Department of Medicine